Skip to content

Epidemiology and Prognosis of ARDS After Pulmonary Resection Surgery

Epidemiology and Prognosis of ARDS After Pulmonary Resection Surgery

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04818554
Acronym
ARDS_THO
Enrollment
50
Registered
2021-03-26
Start date
2012-01-01
Completion date
2021-12-01
Last updated
2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS, Pulmonary Restrictive Disease, Thoracic

Keywords

Thoracic surgery, ARDS, Pulmonary resection, Ventilation

Brief summary

The improvement in ARDS mortality over the last 20 years seems to be largely explained by the reduction of mechanical ventilation-induced injury (VILI). VILI is essentially related to volotrauma closely associated with strain and stress. The pulmonary stress corresponds to the transpulmonary pressure (alveolar pressure - pleural pressure), and the strain to the change in lung volume related to the functional residual capacity (FRC) of the injured lung at PEEP = 0. The volotrauma corresponds therefore to the generalized excess of stress and strain on the injured lung. The initial therapeutic strategy consists in protective ventilation with a tidal volume of 6 ml/kg of theoretical ideal weight (predicted by height), associated with a high respiratory rate between 25 and 30 cycles per minute to control PaCO2 (\< 50 mmHg), apply a high positive expiratory pressure PEEP according to FiO2, maintain a plateau pressure (PP) lower than 30 cmH20, reduce instrumental dead space, use curarization, recruitment maneuvers such as alternate prone, improve ventilation-perfusion adequacy using inhaled NO. As a last resort, extracorporeal oxygenation by veno-venous ECMO is a device to supplement respiratory function by improving oxygenation and ensuring decarboxylation. Veno-venous ECMO is indicated in severe ARDS with PaO2/FiO2 \< 80 mmHg and/or when mechanical ventilation becomes unsafe due to increased plateau pressure despite optimized ARDS management including high PEEP levels, curarization and prone position. After lung resection surgery, the incidence of ARDS is 2-8% and its prognosis remains more poor, despite advances in management, with a mortality of up to 60%. Risk factors include intraoperative vascular filling, type of pulmonary resection, and predicted postoperative respiratory function. Early support with VV ECMO is vital in some patients to treat severe hypoxemia, due to variable surgical reduction of lung parenchyma depending on carcinological involvement or initial lung pathology. ). There are very few data concerning these patients with pulmonary resection. The primary objective of this study is to describe the prevalence of ARDS and the risk factors for its occurrence after pulmonary resection surgery. The secondary objective is to compare the ventilation parameters (especially motor pressure) in patients with reduced lung parenchyma in ARDS under VV ECMO with those who did not use VV ECMO assistance.

Interventions

None listed

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Patient hospitalized following ARDS after thoracic resection surgery

Exclusion criteria

\- Refusal to participate after receiving the information letter

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of ARDS1 dayPrevalence of ARDS after pulmonary resection surgery
risk factors for its occurrence after pulmonary resection surgery1 dayrisk factors for its occurrence after pulmonary resection surgery

Secondary

MeasureTime frameDescription
According to the usual clinico-biological data of monitoring in intensive care1 dayAccording to the usual clinico-biological data of monitoring in intensive care

Countries

France

Contacts

Primary ContactHélène David, PHD
h-david@chu-montpellier.fr629834346

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026